Peutz-Jeghers Syndrome
Basics
Description
- Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant (AD), inherited condition characterized by the development of unique benign hamartomatous polyps throughout the gastrointestinal (GI) tract in association with mucocutaneous hyperpigmentation, most notably of the lips.
- Although malignancy most commonly occurs in the small bowel, PJS also carries an increased risk for developing extraintestinal malignancies—mainly breast, gynecologic, and pancreatic.
Epidemiology
Incidence
- PJS appears equally in males and females, without any ethnic predominance.
- Median age of diagnosis is 15 years but with wide variability (range 3.7 to 45.4 years of age).
- The incidence of PJS in the United States has been estimated to be approximately 1:8,300 and 1:200,000 per year.
Prevalence
PJS occurs at a prevalence of approximately 1/100,000 population.
Etiology and Pathophysiology
- Mucocutaneous lesions
- Secondary to increased melanin in basal cells, which is possibly due to an inflammatory block on melanin migration from melanocytes to keratinocytes
- Polyps (hamartomas)
- Found throughout the GI tract, but most are located in the small bowel (60–90%) and colon (50–64%)
- May be located in extraintestinal sites, including gallbladder, respiratory tract, and bladder
- Proposed theories of polyps suggest they may result from a mechanical process/stromal neoplasia.
- Proposed pathways:
- Role of the PJS polyp in cancer development can be supported by a unique “hamartoma-adenoma-carcinoma pathway” due to the findings of adenomatous foci and malignant foci within PJS polyps.
- Some suggest no malignant potential within PJS polyps and that cancer arises from mucosal instability via conventional neoplastic pathways involving proliferation of mutant cell lines.
Genetics
- AD with high degree of penetrance for polyposis, skin pigmentation, and cancer
- Germline mutations
- Can be found in STK11 gene (19p13.3)—a tumor suppressor gene—encoding a serine-threonine kinase; occurs in up to 94% of patients who fulfill the diagnostic criteria
- K-RAS in a mutated form may increase risk of PJS-associated cancers.
General Prevention
- Smoking cessation should be encouraged in all patients with PJS to avoid the added risk for malignancy development.
- Clinical awareness and early diagnosis are important. Affected patients and at-risk family members should be offered genetic counseling and surveillance.
Commonly Associated Conditions
- Common
- Characteristic hyperpigmentation can be seen in up to 90% of PJS patients.
- Polyp-related symptoms usually arise in childhood, with 33% of patients by age 10 years requiring laparotomy.
- GI polyps are at risk of acute bleeding, intussusception, and bowel obstruction.
- Anemia due to occult blood loss, hematochezia (intestinal polyps), or hematemesis (gastric/duodenal polyps, less common) may be seen.
- Recurrent abdominal pain due to intussusception in 50% of patients by age 20 years
- Rare
- Bowel ischemia secondary to bowel infarction
- Cancers: The overall cumulative risk for cancer has been estimated at >76% in PJS patients.
- The relative risk of developing malignancy is highest in the small bowel, with a median age of 41 years and significant increase after age 50 years.
- Studies have shown that the risks of cancers are similar in those patients with identified mutations in STK11 as well as those without.
- Risk of cancer is higher in females than males.
- The associated cancers commonly include (frequency, %) breast (54%), colorectal (39%), pancreatic (36%), gastric (29%), and small bowel (13%).
- The increased risk of extraintestinal malignancy is largely due to breast and gynecologic cancers in women along with pancreatic cancer, particularly in men.
- The risk for breast cancer among PJS patients is similar to that of women with BRCA1/BRCA2 mutations.
- K-RAS mutation can lead to lobular endocervical glandular hyperplasia, which increases the risk of developing cervical cancer.
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Domino, Frank J., et al., editors. "Peutz-Jeghers Syndrome." 5-Minute Clinical Consult, 33rd ed., Wolters Kluwer, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688780/all/Peutz_Jeghers_Syndrome.
Peutz-Jeghers Syndrome. In: Domino FJF, Baldor RAR, Golding JJ, et al, eds. 5-Minute Clinical Consult. Wolters Kluwer; 2025. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688780/all/Peutz_Jeghers_Syndrome. Accessed October 11, 2024.
Peutz-Jeghers Syndrome. (2025). In Domino, F. J., Baldor, R. A., Golding, J., & Stephens, M. B. (Eds.), 5-Minute Clinical Consult (33rd ed.). Wolters Kluwer. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688780/all/Peutz_Jeghers_Syndrome
Peutz-Jeghers Syndrome [Internet]. In: Domino FJF, Baldor RAR, Golding JJ, Stephens MBM, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2025. [cited 2024 October 11]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688780/all/Peutz_Jeghers_Syndrome.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Peutz-Jeghers Syndrome
ID - 1688780
ED - Domino,Frank J,
ED - Baldor,Robert A,
ED - Golding,Jeremy,
ED - Stephens,Mark B,
BT - 5-Minute Clinical Consult, Updating
UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688780/all/Peutz_Jeghers_Syndrome
PB - Wolters Kluwer
ET - 33
DB - Medicine Central
DP - Unbound Medicine
ER -